Academic Article
RDF
pages:
-
A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects.
-
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
-
A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects
-
A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer
-
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
-
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
-
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases
-
A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
-
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma
-
A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer
-
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer
-
A Phase I study of high-dose cisplatin, prolonged infusion 5- fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck
-
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
-
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck
-
A phase I study of T101-ricin a chain immunotoxin in refractory chronic lymphocytic leukemia
-
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
-
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer
-
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
-
A phase I trial of recombinant human interferon-γ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)
-
A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients.
-
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors
-
A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants
-
A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
-
A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers
-
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma
-
A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients
-
A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis
-
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
-
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
pages:
